Lv218
188 积分 2024-06-07 加入
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
15天前
已完结
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
16天前
已完结
Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials
1个月前
已完结
T cell engagers in autoimmune diseases
1个月前
已完结
Bispecific T-cell Engager (CD3 × EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor-Refractory NSCLC
1个月前
已完结
Trispecific anti-CLDN-18.2/CD3/CD28 antibodies for gastric cancer treatment
3个月前
已完结
Enhancing the activation of T cells through anti‐CD3/CD28 magnetic beads by adjusting the antibody ratio
4个月前
已完结
Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation
4个月前
已完结
Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer
4个月前
已完结
Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer
4个月前
已完结
皖公网安备34019202002308
